From this evidence, it is clear that, to kill cancer cells, the choice between CHK2 inhibition and activation depends on many variables such as the kind, magnitude and duration of exposure to the damaging agent, the genetic background of the cancer cells, and the specificity and efficacy of the CHK2 inhibitor. Here, CHEK2 is linked to cancer.